Atlas Venture Life Science Advisors, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 9, 2024), Atlas Venture Life Science Advisors, LLC reported 15 stock positions worth $949.6 million. Its top holding was Dyne Therapeutics (DYN) at 29.8% of the portfolio, followed by Kymera Therapeutics (KYMR, 16.8%) and Third Harmonic Bio (THRD, 14.9%). Compared with Q1 2024, it opened 1 new position, sold out of 2, added to 2 and reduced 4. The biggest buy was a new position in Tectonic Therapeutic (TECX) and the biggest sale Aerovate Therapeutics (shares −12%).
- Most Recent 13F
- Q2 2026
- Location
- CAMBRIDGE, MA
- CIK
- 0001917529
- Portfolio Value
- $949.6M (Q2 2024)
- SEC Filing
- 0001104659-24-087431 ↗ filed Aug 9, 2024
Holdings Value
Holdings 15 stocks · $949.6M
| DYN Dyne Therapeutics Inc. | 29.80% | 8,020,136 | $283.0M | No change |
| KYMR Kymera Therapeutics Inc. | 16.82% | 5,350,422 | $159.7M | Reduce -0.5% |
| THRD Third Harmonic Bio Inc. | 14.93% | 10,907,859 | $141.8M | No change |
| IRON Disc Medicine Inc. | 11.91% | 2,509,456 | $113.1M | Add +9.7% |
| DAWN Day One Biopharmaceuticals I | 9.33% | 6,430,257 | $88.6M | No change |
| KRRO Korro Bio Inc. | 4.06% | 1,137,149 | $38.5M | Add +1.6% |
| QTTB Q32 Bio Inc. | 3.95% | 2,092,106 | $37.6M | No change |
| GBIO Generation Bio Co. | 2.46% | 8,279,484 | $23.3M | No change |
| VIGL Vigil Neuroscience Inc. | 2.46% | 5,836,874 | $23.3M | No change |
| REPL Replimune Group Inc. | 1.99% | 2,098,300 | $18.9M | No change |
| IKENA ONCOLOGY INC | 0.87% | 5,018,178 | $8.3M | No change |
| TECX Tectonic Therapeutic Inc. | 0.66% | 378,447 | $6.2M | New |
| DNTH Dianthus Therapeutics Inc. | 0.37% | 136,979 | $3.5M | Reduce -26.7% |
| AEROVATE THERAPEUTICS INC | 0.31% | 1,799,232 | $3.0M | Reduce -11.8% |
| SPRO Spero Therapeutics Inc. | 0.07% | 535,336 | $696K | Reduce -11.9% |
Portfolio Sells Q1 2024 → Q2 2024
| AEROVATE THERAPEUTICS INC | Reduce -11.8% | 0.31% | −5.25 |
| KYMR Kymera Therapeutics Inc. | Reduce -0.5% | 16.82% | −3.13 |
| AVROBIO INC | Sold out | 0.00% | −0.54 |
| DNTH Dianthus Therapeutics Inc. | Reduce -26.7% | 0.37% | −0.14 |
| XLO Xilio Therapeutics Inc. | Sold out | 0.00% | −0.10 |
| SPRO Spero Therapeutics Inc. | Reduce -11.9% | 0.07% | −0.02 |
Portfolio Buys Q1 2024 → Q2 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 7 | $881.3M | KYMR, DYN, SION, KLRA, IRON |
| Q1 2026 | 6 | $790.0M | KYMR, DYN, SION, IRON, QTTB |
| Q4 2025 | 8 | $865.2M | KYMR, DYN, SION, IRON, DAWN |
| Q3 2025 | 9 | $752.6M | KYMR, IRON, DYN, SION, KRRO |
| Q2 2025 | 11 | $662.4M | KYMR, IRON, DYN, SION, THRD |
| Q1 2025 | 13 | $521.8M | KYMR, IRON, DYN, DAWN, SION |
| Q4 2024 | 13 | $819.7M | KYMR, DYN, IRON, THRD, DAWN |
| Q3 2024 | 14 | $1.1B | DYN, KYMR, THRD, IRON, QTTB |
| Q2 2024 | 15 | $949.6M | DYN, KYMR, THRD, IRON, DAWN |
| Q1 2024 | 16 | $1.1B | DYN, KYMR, IRON, DAWN, THRD |